Clinical trial
Efficacy Study of Digibind for Treatment of Severe Preeclampsia
NCT00158743 · BTG International Inc., Other · Completed
Key facts
| NCT number | NCT00158743 |
|---|---|
| Title | Efficacy Study of Digibind for Treatment of Severe Preeclampsia |
| Official title | A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia |
| Lead sponsor | BTG International Inc., Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pre-eclampsia |
| Intervention type | Drug, Other |
| Interventions | Anti-digoxin antibody (FAB fragment), sodium chloride |
| Enrollment | 51 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 8, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: